< IP News

Amgen to Purchase Otezla® (apremilast) from Celgene Corporation

Amgen has announced that it has agreed to purchase worldwide rights to Otezla® (apremilast) from Celgene Corporation for US $13.4 billion. Otezla® provides an oral therapy for the treatment of psoriasis and psoriatic arthritis and is seen by Amgen as a strategic acquisition that complements its existing line of products directed at treating inflammatory conditions. In particular, Otezla® is a non-biologic medication, while Amgen’s existing Enbrel® (etanercept) is a biologic and AMGEVITA® is an adalimumab biosimilar.  Both of these existing products are also marketed for the treatment of various inflammatory diseases.

This agreement follows the announcement by Britsol-Myers Squibb Company of its intent for the divestiture of Otezla® to allow for the timely completion of its merger with Celgene Corporation in light of the U.S. Federal Trade Commission’s review.

In 2018, Otezla®’s sales were $1.6 billion. Amgen’s announcement of the $13.4 billion deal cites Otezla®’s patent exclusivity through at least 2028 in the U.S., suggesting patent protection for Otezla® created greater value for the product and helped secure the significant amount of the deal.

Read more here.

Information made available on this website in any form is for information purposes only. It is not, and should not be taken as legal advice. You should not rely on, or take or fail to take any action, based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Oyen Wiggs Green & Mutala LLP professionals will be pleased to discuss resolutions to specific legal concerns you may have.